| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/03/2010 | EP2148699A1 Vaccination regimen for b-cell vaccines |
| 02/03/2010 | EP2148675A1 Anti-cancer medicine both for diagnosing and treating cancer |
| 02/03/2010 | EP2148661A1 Oral controlled release compositions comprising vitamin d compound and waxy carrier |
| 02/03/2010 | EP1421938B1 Antitumor agents and process for producing the same |
| 02/03/2010 | EP1351679B1 Method and composition for the treatment of diabetic neuropathy |
| 02/03/2010 | EP1301208B1 Mannose as intranasal vaccine adjuvant |
| 02/03/2010 | EP1078636B1 Pharmaceutical composition for use in emergency treatment and preparation method thereof |
| 02/03/2010 | CN101641118A Cyclodextrin inclusion complexes and methods of preparing same |
| 02/03/2010 | CN101637610A Carrageenan soft capsule material and preparation method thereof |
| 02/03/2010 | CN100586497C Ultrasonic device for wound treatment |
| 02/03/2010 | CN100586481C Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/03/2010 | CN100586480C A sodium alginate microsphere vascular embolizing agent containing water soluble drug, its preparation and application |
| 02/03/2010 | CN100586479C Application of cyanoacrylate glycol ester in preparing medicine carrier |
| 02/03/2010 | CN100586423C Popping oral pharmaceutical compositions |
| 02/02/2010 | US7655766 Partially dePEGylated lysine/N-terminal positional PEG isomers of a recombinant G-CSF polypeptide, such recombinant G-CSF polypeptide containing the substitutions K16R, K34R, K40R, T105K and S159K relative to wild-type human G-CSF; increasing the level of neutrophils in a patient |
| 02/02/2010 | US7655758 Tumor rejection antigen precursor fusion protein capable of binding to IL-1; histidine buffer; polyethylene glycol organic co-solvent or bulking agent; glycine, arginine, sucrose lyoprotectants; prefilled dual-chambered receptacle, single use injectable dose |
| 02/02/2010 | US7655753 Conjugate |
| 02/02/2010 | US7655747 hydrolytically unsatable linkages including estes, acetals, imines, peptides, protiens, oligonucleotides near the reactive end of polymer provide for a sufficient ciculation period for drug-polymer conjugate, hydrolytically breakdown the conjugate to release bound drug; slowing rate of kidney clearance |
| 02/02/2010 | US7655717 Ointment composition for treating decubitus ulcers and methods for its making and its use |
| 02/02/2010 | US7655694 Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury |
| 02/02/2010 | US7655661 Prodrugs of CC-1065 analogs |
| 02/02/2010 | US7655660 Antitumor antibiotic; water solubility, stability; N-[2-{(1-chloromethyl)-1,2-dihydro-5-[(4-methylpiperazino)carbonyloxy]-3H-benz(e)indol-3-yl}carbonyl]-1H-indol-5-yl]-5-[(3-methyldithio-1-oxopropyl)-amino]-1H-indole-2-carboxamide |
| 02/02/2010 | US7655630 Abuse-resistant amphetamine prodrugs |
| 02/02/2010 | US7655624 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 02/02/2010 | US7655619 Insulin-associated peptides with effects on cerebral health |
| 02/02/2010 | US7655617 Conjugates of soluble peptidic compounds with membrane-binding agents |
| 02/02/2010 | US7655616 Traumatic brain and spinal cord injury treatment; administering interleukin-1B converting enzyme (capsase-1) inhibitor |
| 02/02/2010 | US7655435 For eukaryotic in vitro expression; silicone-based surfactants and microcapsules; phage display |
| 02/02/2010 | US7655256 Pharmaceutical formulation including a resinate and an aversive agent |
| 02/02/2010 | US7655226 Treatment of Pompe's disease |
| 02/02/2010 | CA2477756C Modified phosphocalcic compound, injectable composition containing same |
| 02/02/2010 | CA2468563C Calcium metasilicates and methods for making the same |
| 02/02/2010 | CA2465090C Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| 02/02/2010 | CA2460306C Stable and taste masked pharmaceutical dosage form using porous apatite grains |
| 02/02/2010 | CA2436752C Bifidobacteria and preparations containing them |
| 02/02/2010 | CA2430791C Ionophore antibiotic formulations |
| 02/02/2010 | CA2407994C Reductive alkylation process |
| 02/02/2010 | CA2383412C Cationic liposome delivery of taxanes to angiogenic blood vessels |
| 02/02/2010 | CA2321819C Xylitol compositions for treating upper respiratory conditions |
| 02/02/2010 | CA2257973C T cell antigen receptor peptides |
| 02/02/2010 | CA2204277C Combined meningitis vaccine |
| 01/28/2010 | WO2010011609A2 Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| 01/28/2010 | WO2010011605A2 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| 01/28/2010 | WO2010011585A2 Ophthalmic device having therapeutic agent delivery capability and method of forming same |
| 01/28/2010 | WO2010011327A2 Radiative heating for drug delivery and other applications |
| 01/28/2010 | WO2010011326A2 Heating of polymers-and other materials using radiation for drug delivery and other applications |
| 01/28/2010 | WO2010011319A2 Magnetic heating for drug delivery and other applications |
| 01/28/2010 | WO2010011119A1 Ophthalmic solution for corneal enlargement |
| 01/28/2010 | WO2010010902A1 Microcapsule, process for production thereof, and food or beverage containing microcapsule |
| 01/28/2010 | WO2010010756A1 Water-soluble acrylic acid salt polymer and gelling base |
| 01/28/2010 | WO2010010715A1 Stable aqueous solution composition containing sulfonamide compound |
| 01/28/2010 | WO2010010689A1 Liquid preparation for contact lenses |
| 01/28/2010 | WO2010010531A2 Composition for controlling increase in blood glucose |
| 01/28/2010 | WO2010010470A2 Methods of administering topical antifungal formulations for the treatment of fungal infections |
| 01/28/2010 | WO2010010324A1 Novel reagents and method for conjugating biological molecules |
| 01/28/2010 | WO2010010112A2 Construct and method for the internalization of cargo molecules into a cell |
| 01/28/2010 | WO2010009745A1 Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
| 01/28/2010 | WO2010009661A1 Emulsion composition, methods of softening fibrous structures using the same, and fibrous substrate treated therewith |
| 01/28/2010 | WO2009132153A3 Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same |
| 01/28/2010 | WO2009129456A3 Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
| 01/28/2010 | WO2009129432A3 Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| 01/28/2010 | WO2009129149A4 Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| 01/28/2010 | WO2009129148A3 Methods and compositions for treating intervertebral disc herniations |
| 01/28/2010 | WO2009126933A3 Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| 01/28/2010 | WO2009099670A3 Oligomer-cannabinoid conjugates |
| 01/28/2010 | WO2009082607A8 Targeting lipids |
| 01/28/2010 | WO2009075859A3 Formulation of insulinotropic peptide conjugates |
| 01/28/2010 | WO2009073445A3 Biocompatible biodegradable fumagillin analog conjugates |
| 01/28/2010 | WO2009054551A3 Lipid-modified double-stranded rna having potent rna interference effect |
| 01/28/2010 | WO2009042064A3 Oligomer-nucleoside phosphate conjugates |
| 01/28/2010 | WO2009024977A3 Saccharide-containing protein conjugates and uses thereof |
| 01/28/2010 | US20100022750 Targeted Delivery of Antimicrobial Agents |
| 01/28/2010 | US20100022665 Oil-in-water emulsion cosmetic composition and method for producing the same |
| 01/28/2010 | US20100022664 Process for the partial hydrogenation of fatty acid esters |
| 01/28/2010 | US20100022661 Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| 01/28/2010 | US20100022643 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 01/28/2010 | US20100022588 Pharmaceutical carrier composition and pharmaceutical composition |
| 01/28/2010 | US20100022577 Dry syrup containing loratadine |
| 01/28/2010 | US20100022498 Steroids as agonists for fxr |
| 01/28/2010 | US20100022481 Drug Carriers, Their Synthesis, and Methods of Use Thereof |
| 01/28/2010 | US20100022479 Cellular gradient polymer composites |
| 01/28/2010 | US20100022439 Nanostructures with High Load of Active Agents |
| 01/28/2010 | US20100021565 Pearlescent Pigments |
| 01/28/2010 | US20100021553 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
| 01/28/2010 | US20100021551 Process for preparing nanoparticles of chitosan in water phase |
| 01/28/2010 | US20100021547 Pharmaceutical composition for piperidinoalkanol compounds |
| 01/28/2010 | US20100021545 Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof |
| 01/28/2010 | US20100021544 Hydrogel and biomedical applications thereof |
| 01/28/2010 | US20100021542 Extended release oral dosage composition |
| 01/28/2010 | US20100021535 Light-stabilized soft capsule formulations |
| 01/28/2010 | US20100021534 Injection-molded water soluble container |
| 01/28/2010 | US20100021489 comprising an RNA sequence capable of specifically binding a polypeptide participating in influenza virus infection of cells |
| 01/28/2010 | US20100021442 Method for promoting immunotherapy using an agent for elevating dendritic cell precursor level in blood |
| 01/28/2010 | US20100021419 Stable Pharmaceutical Composition Comprising Granulocyte-Colony Stimulating Factor |
| 01/28/2010 | US20100021416 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| 01/28/2010 | US20100018865 Electrolyte solution and method for electrolytic co-deposition of thin film calcium phosphate and drug composites |
| 01/28/2010 | CA2731769A1 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| 01/28/2010 | CA2731766A1 Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| 01/28/2010 | CA2731455A1 Methods of administering topical antifungal formulations for the treatment of fungal infections |
| 01/28/2010 | CA2731271A1 Stable aqueous solution composition containing sulfonamide compound |